Company Overview of Marie Curie Cancer Care
Key Executives for Marie Curie Cancer Care
Head of Policy and Public Affairs for England
Head of Policy and Public Affairs for Wales
Compensation as of Fiscal Year 2014.
Marie Curie Cancer Care Key Developments
Curie-Cancer and Servier Renew Partnership
Jan 29 14
Servier and Curie-Cancer announced to renew their partnership on research and development of treatment candidates for triple-negative breast cancers. The partnership has been extended by three years. The agreement between Servier and the Institut Curie was first signed in 2005 and focused on breast and colon cancer drugs. The partnership is in line with Servier's business strategy focusing on partnerships with major research centres. In particular, the oncology segment of Servier is a major share of the company's research and development pipeline and the renewal of the partnership is likely to further enhance Servier's focus on this research area. In addition, research on triple-negative breast cancers may offer the opportunity to address a typology of breast cancer that is not responsive to chemotherapy treatments and accounts for approximately 15% of overall breast cancer cases.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries